Dermatology : international journal for clinical and investigative dermatology
-
Dermatology (Basel) · Jan 2010
A nonsense mutation in the SCN9A gene in congenital insensitivity to pain.
Congenital insensitivity to pain (CIP) (OMIM 243000) is a rare autosomal-recessive disorder. Clinically, CIP is characterized by insensitivity to all modalities of pain except neuropathic pain, and recurrent injuries frequently go unnoticed. CIP is caused by mutations in the SCN9A gene encoding for the Na1.7 channel. ⋯ We identified a novel mutation in the Na1.7 channel leading to CIP, extending the spectrum of mutations in the Na1.7 channel, and enhancing our understanding of the physiology of pain.
-
Dermatology (Basel) · Jan 2010
Randomized Controlled TrialTumescent liposuction: efficacy of a lower lidocaine dose (400 mg/l).
Local anesthesia has been widely accepted as the standard of care in liposuction. Anesthesia is achieved with a standard tumescent solution, and lidocaine is most often used at a concentration of 500 mg/l. ⋯ We propose the use of a lower lidocaine concentration of 400 mg/l in the tumescent solution compared to the originally described solution containing 500 mg/l. This is of particular interest when multiple body parts or larger areas are to be treated to avoid lidocaine toxicity.
-
Hidradenitis suppurativa (HS) may be associated with face and back lesions which are considered as acne. ⋯ Some HS patients have specific lesions of the face and back which are not acne and have to be treated differently.
-
Dermatology (Basel) · Jan 2009
Case ReportsNew indications for artificial collagen-elastin matrices? Covering exposed tendons.
We present an 80-year-old patient who presented a defect with exposed tendons on the dorsum of the hand after micrographic controlled tumour excision. The defect was closed using a combination of artificial collagen-elastin matrix (Matriderm) covered by an autologous split-skin graft in a 1-step approach resulting in rapid healing and good functional and cosmetic results.
-
Dermatology (Basel) · Jan 2009
Case ReportsIntravascular large B-cell lymphoma of the skin: typical clinical manifestations and a favourable response to rituximab-containing therapy.
Intravascular large B-cell lymphoma (IVBCL) is a rare malignant neoplasm characterized by the proliferation of large B cells within the blood vessels. The disease can be limited to the skin, but involvement of other organs is common. We report a case of cutaneous IVBCL in a 62-year-old man with minimal histological changes in contrast to prominent skin lesions. The patient was successfully treated with rituximab in combination with CHOP chemotherapy.